BioMark Diagnostics Inc.
BUX
Rang in aandelen
#26615
BioMark Diagnostics Inc. is an oncology specialist, developing advanced... BioMark Diagnostics Inc. is an oncology specialist, developing advanced diagnostic tools for cancer to enable early detection, continuous patient monitoring, and the assessment of initial treatment efficacy. The firm holds a research partnership with the Icahn School of Medicine, collaborating on clinical trials specifically addressing the early identification of lung cancer. Founded in 2014, its corporate headquarters are situated in Richmond, Canada. BioMark Diagnostics Inc. operates as a subsidiary of Biomark Technologies Inc.
Aandeelprijs
$0.34495034
Laatst gesynchroniseerd: 2026-10-16
Marktkapitalisatie
$36.73M
Verandering (1 dag)
-4.08%
Verandering (1 jaar)
41.11%
Land
CA
Handel BioMark Diagnostics Inc. (BUX)
Categorie
Healthcare
Dividendrendementgeschiedenis voor BioMark Diagnostics Inc. (BUX)
Het dividendrendement (TTM) van BioMark Diagnostics Inc. (aandelsymbool: BUX) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van BioMark Diagnostics Inc. (BUX) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
| Jaar | Dividendrendement | Wijzigen |
|---|---|---|
| Niet genoeg gegevens voor de verstrekte datums. | ||
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
| Bedrijf | Dividendrendement | Land |
|---|---|---|
| 0.27% |
US
|
|
| 0.68% |
US
|
|
| 0.00% |
US
|
|
| 0.00% |
CN
|
|
| 0.59% |
US
|
